Efficacy and pathogenetic justification for the use of vildagliptin in patients with type 2 diabetes mellitus
Background. Dipeptidyl peptidase4 inhibitors, having incretin activity, influence the main pathogenetic mechanisms of type 2 diabetes mellitus (DM). Vildagliptin is an innovative dipeptidyl peptidase4 inhibitor with unique pharmacokinetic characteristics, the efficacy and safety of which have be...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Zaslavsky O.Yu.
2019-10-01
|
| Series: | Mìžnarodnij Endokrinologìčnij Žurnal |
| Subjects: | |
| Online Access: | http://iej.zaslavsky.com.ua/article/view/186055 |